Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control

BMC Public Health

Robin L Bailey⁵  Ansumana Sillah³  David C W Mabey⁵  Martin J Holland⁵  Emma M Harding-Esch²  Tansy Edwards⁴  John Hart⁵  Sarah E Burr¹ 

[1] Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia, Fajara, Banjul, The Gambia;Public Health England, HIV/STI Department, Colindale, London, UK;National Eye Health Programme, Ministry of Health, Kanifing, The Gambia;MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK;Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK

关键词: Anthropometry;    Trachoma control;    Azithromycin;    Mass drug administration;   

Others  :  1122952
DOI  :  10.1186/1471-2458-14-1176

 received in 2014-04-30, accepted in 2014-10-27,  发布年份 2014

【 摘 要 】

Background

Mass drug administration (MDA) with azithromycin, carried out for the control of blinding trachoma, has been linked to reduced mortality in children. While the mechanism behind this reduction is unclear, it may be due, in part, to improved nutritional status via a potential reduction in the community burden of infectious disease. To determine whether MDA with azithromycin improves anthropometric indices at the community level, we measured the heights and weights of children aged 1 to 4 years in communities where one (single MDA arm) or three annual rounds (annual MDA arm) of azithromycin had been distributed.

Methods

Data collection took place three years after treatment in the single MDA arm and one year after the final round of treatment in the annual MDA arm. Mean height-for-age, weight-for-age and weight-for-height z scores were compared between treatment arms.

Results

No significant differences in mean height-for-age, weight-for-age or weight-for-height z scores were found between the annual MDA and single MDA arms, nor was there a significant reduction in prevalence of stunting, wasting or underweight between arms.

Conclusions

Our data do not provide evidence that community MDA with azithromycin improved anthropometric outcomes of children in The Gambia. This may suggest reductions in mortality associated with azithromycin MDA are due to a mechanism other than improved nutritional status.

【 授权许可】

   
2014 Burr et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H: Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995, 311:481-485.
• [2]Roth AE, Garly ML, Jensen H, Nielsen J, Aaby P: Bacille Calmette Guerin vaccination and infant mortality. Expert Rev Vaccines 2006, 5:277-293.
• [3]Sommer A, Djunaedi E, Loeden AA, Tarwotjo I, West KP, Tilden R, Mele L, The Aceh Study Group: Impact of vitamin A supplementation on childhood mortality: a randomised controlled community trial. Lancet 1986, 8491:1169-1173.
• [4]Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Brigham H: Treatment with a single dose of albendazole improves growth of Kenyan schoolchildren with hookworm, Trichuris trichiura, and Ascaris lumbricoides infections. Am J Trop Med Hyg 1989, 41:78-87.
• [5]Nokes C, Grantham-McGregor SM, Sawyer AW, Cooper ES, Robinson BA, Bundy DA: Moderate to heavy infections of Trichuris trichiura affect cognitive function in Jamaican school children. Parasitology 1992, 104:539-547.
• [6]Ryan KN, Stephenson KB, Trehan I, Shulman RJ, Thakwalakwa C, Murray E, Maleta K, Manary MJ: Zinc or albendazole attenuates the progression of environmental enteropathy: a randomized controlled trial. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
• [7]WHO: Report of the first meeting of the WHO alliance for the Global Elimination of Trachoma. Geneva: WHO/PBL/GET/97.1; 1997.
• [8]WHO: Report of the third meeting of the WHO Alliance for the Global Elimination of Trachoma. Ouarzazate: WHO/PBD/GET/99.3; 1999.
• [9]WHO: Trachoma Control - a Guide for Programme Managers. Geneva, Switzerland: World Health Organization; 2006.
• [10]Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P, Gaynor BD, Lietman TM: Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009, 302:962-968.
• [11]Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietmand TM: Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011, 52:883-888.
• [12]Guerrant RL, Bartelt LA, Scharf RJ: Thinking deeper about important mass treatment trials. Clin Infect Dis 2012, 54:1674-1675.
• [13]Gough EK, Moodie EEM, Prendergast AJ, Johnson SMA, Humphrey JH, Stoltzfus RJ, Walker AS, Trehan I, Gibb DM, Goto R, Tahan S, Manges AR, de Batista Morais M: The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 348:g2267.
• [14]Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque ASG, Zaidi AKM, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, et al.: Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case–control study. Lancet 2013, 382:209-222.
• [15]Rowland MG, Rowland SG, Cole TJ: Impact of infection on the growth of children from 0 to 2 years in an urban West African community. Am J Clin Nutr 1988, 47:134-138.
• [16]Eccles MP, Cole TG, Whitehead RG: Identification of factors influencing infant growth in developing countries. Arch Dis Child 1989, 64:1559-1565.
• [17]Weisz A, Meuli G, Thakwalakwa C, Trehan I, Maleta M, Manary M: The duration of diarrhea and fever is associated with growth faltering in rural Malawian children aged 6–18 months. Nutr J 2011, 10:25. BioMed Central Full Text
• [18]Whitty CJ, Glasgow KW, Sadiq ST, Mabey DC, Bailey R: Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr Infect Dis J 1999, 18:955-958.
• [19]Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S: Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg 2011, 85:691-696.
• [20]Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S: Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J 2012, 31:341-346.
• [21]Lunn PG: The impact of infection and nutrition on gut function and growth in childhood. Proc Nutr Soc 2000, 59:147-154.
• [22]Weisz AJ, Manary MJ, Stephenson K, Agapova S, Manary FG, Thakwalakwa C, Shulman RJ, Manary MJ: Abnormal gut integrity is associated with reduced linear growth in rural Malawian children. J Pediatr Gastroenterol Nutr 2012, 55:747-750.
• [23]Panter-Brick C, Lunn PG, Langford RM, Maharjan M, Manandhar DS: Pathways leading to early growth faltering: an investigation into the importance of mucosal damage and immunostimulation in different socio-economic groups in Nepal. Br J Nutr 2009, 101:558-567.
• [24]Goto R, Mascie-Taylar CG, Lunn PG: Impact of intestinal permeability, inflammation status and parasitic infections on infant growth faltering in rural Bangladesh. Br J Nutr 2009, 101:1509-1516.
• [25]Humphrey JH: Child undernutrition, tropical enteropathy, toilets and handwashing. Lancet 2009, 374:1032-1035.
• [26]Giamarellos-Bourboulis EJ: Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008, 31:12-20.
• [27]Stare D, Harding-Esch E, Munoz B, Bailey R, Mabey D, Holland M, Gaydos C, West S: Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmid Epidemiol 2011, 18:20-29.
• [28]Harding-Esch EM, Edwards T, Mkocha H, Munoz B, Holland MJ, Burr SE, Sillah A, Gaydos CA, Stare D, Mabey DC, Bailey RL, Wesk SK, PRET Partnership: Trachoma prevalence and associated risk factors in The Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Negl Trop Dis 2010, 4:e861.
• [29]Harding-Esch EM, Sillah A, Edwards T, Burr SE, Hart JD, Joof H, Laye M, Makalo P, Manjang A, Molina S, Sarr-Sissoho I, Quinn TC, Lietmand T, Holland MJ, Mabey D, Wesk SK, Bailey R, PRET Study Group: Mass treatment with azithromycin for trachoma: when is One round enough? results from the PRET trial in the Gambia. PLoS Negl Trop Dis 2013, 7:e2115.
• [30]Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, Chin S, West SK, Bailey RL, Mabey DC, Keenan JD, Porco TC, Lietmand TM, Gaynor BD, PRET Partnership: Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. PLoS Negl Trop Dis 2012, 6:e1586.
• [31]Basilion EV, Kilima PM, Turner VM, Mecaskey JW: Height as a proxy for weight in determining azithromycin treatment for paediatric trachoma. T Roy Soc Trop Med H 2002, 96:691-694.
• [32]WHO: Physical status: the use and interpertation of anthropometry: 1–8 November 1993. Geneva: WHO/TRS/854; 1995.
• [33]Victora CG, De Onis M, Hallal PC, Blössner M, Shrimpton R: Worldwide timing of growth faltering: revisiting implications for interventions. Pediatrics 2010, 125:e473-e480.
• [34]Leonor Rodríguez L, Cervantes E, Ortiz R: Malnutrition and gastrointestinal and respiratory infections in children: a public health problem. Int J Environ Res Public Health 2011, 8:1174-1205.
• [35]Edwards T, Allen E, Harding-Esch EM, Hart J, Burr SE, Holland MJ, Sillah A, West SK, Mabey DCW, Bailey RL: Non-participation during azithromycin mass treatment for trachoma in the Gambia: heterogeneity and risk factors. PLoS Negl Trop Dis 2014, 8:e3098.
• [36]Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, West SK, Mabey DC, Bailey RL, Keenan JD, Porco TC, Lietmand TM, Gaynor BD: A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in Niger. Am J Trop Med Hyg 2013, 88:138-143.
• [37]Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, Zhou Z, House J, Ray K, Porco T, Rutar T, Keenan J, Lietman TM, Gaynor BD: The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 2010, 51:571-574.
• [38]Rowland MG, Cole TJ, Whitehead RG: A quantitative study into the role of infection in determining nutritional status in Gambian village children. Br J Nutr 1977, 37:441-450.
• [39]WHO: WHO vaccine-preventable diseases: monitoring system, 2013 global summary coverage time series for Gambia (the) (GMB). [http://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=GMB&commit=OK webcite]
• [40]Udan I, O’Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, Luksic I, Fischer Walker CL, Balck RE, Campbell H: Child Health Epidemiology Reference Group (CHERG): epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013, 3:010401.